DaVita Labs to Present Falcon Lab Application at National Renal Administrators Association 2011 Annual Meeting
October 03 2011 - 9:38AM
Business Wire
DaVita Labs, a chronic kidney disease specialty laboratory, will
display the company’s latest version of its Web-based application,
Falcon Lab™, at the National Renal Administrators Association
(NRAA) 2011 Annual Meeting.
The October 5-7 meeting will be held at the New Orleans Marriott
in New Orleans. The company will be located at booth #202 during
the meeting.
Falcon Lab™ is designed as a renal-specific, Web-based
application that provides 24/7 access to advanced ordering, data
analysis and reporting tools for patients with CKD and ESRD. Falcon
Lab demonstrations are available at NRAA by scheduling an
appointment with Brenda Lavati at brenda.lavati@davita.com.
Falcon Lab’s new regulatory reporting package provides the
organizations and facilities with a detailed
statistical analysis and exception reports to assist in
managing QIP measures and QAPI with ease.
“With its simplified design, Falcon Lab streamlines the
reporting process,” said DaVita LabsSM General Manager Leslie
Mirani. “This software allows physicians to access into the
patient’s history and easily creates detailed patient and facility
reports with trend-indicating graphs. Physicians can also build and
manage commonly ordered lab panels, generate customized panels
based on co-morbid conditions, and electronically sign or dispute
orders with the click of a mouse.”
Additionally, DaVita Labs provides the following:
- Face-to-face onboarding support
- Quarterly face-to-face visits on
site
- Monthly operations review
- Significant infrastructure investment
(IT, laboratory operations, plant & equipment)
- State lab reporting that meets
customer’s needs (QAPI, QIP & CROWN web)
- National insurance coverage
- Industry knowledge
- 24/7 resources for operational
specialist support, dietitian support & clinical process
support
Between its two locations in Ft. Lauderdale and Deland, Fla.,
DaVita Labs has 86,700 square feet dedicated to its
state-of-the-art clinical diagnostic. The laboratories feature the
latest in renal-specific methodology and technology for delivering
quality test results. The DaVita Labs clinical laboratory team is
led by experienced scientists and pathologists, and receives formal
guidance from top nephrologists in the industry.
DaVita, DaVita Labs and Falcon Lab are trademarks or registered
trademarks of DaVita Inc. All other trademarks are the property of
their respective owners.
About DaVita Labs
DaVita Labs, a division operating within DaVita
Inc., provides quality, on-time, accurate results to help
effectively identify and manage kidney patients across the nation.
As a cutting-edge chronic kidney disease (CKD) specialty
laboratory, DaVita Labs features the latest in end stage renal
disease-specific methodology and technology for delivering quality
dialysis test results. DaVita Labs is fully accredited by the
federal and state governmental agencies, and the College of
American Pathologists. For more information, please visit
www.davitalabs.com or call 877-200-3181.
About DaVita
DaVita Inc. (NYSE: DVA), a Fortune 500® company, is a leading
provider of kidney care in the United States, delivering dialysis
services to patients with chronic kidney failure and end stage
renal disease. DaVita strives to improve patients’ quality of life
by innovating clinical care, and by offering integrated treatment
plans, personalized care teams and convenient health-management
services. As of June 30, 2011, DaVita operated or provided
administrative services at 1,669 dialysis facilities, serving
approximately 131,000 patients. DaVita supports numerous programs
dedicated to creating positive, sustainable change in communities
around the world. The company’s leadership development initiatives
and social responsibility efforts have been recognized by Fortune,
Modern Healthcare, Newsweek and WorldBlu. For more information,
please visit www.davita.com.
DaVita (NYSE:DVA)
Historical Stock Chart
From Sep 2024 to Oct 2024
DaVita (NYSE:DVA)
Historical Stock Chart
From Oct 2023 to Oct 2024